Ask AI
ProCE Banner Series

SignateraTM Ultrasensitive MRD Testing for Head and Neck Cancer Patient Care

Join Dr. Abhinand Peddada MD and Dr. Michael Krainock MD, PhD as they review the latest clinical data supporting the use of ctDNA for molecular residual disease (MRD) assessment in HNSCC.

Learn how MRD testing has been shown to stratify patients by recurrence risk following curative intent treatment, detect recurrence before radiographic imaging, and predict which patients may benefit from immune checkpoint inhibitor treatment.

The webinar will conclude with a review of real world case studies, practical considerations for implementing MRD testing in routine practice, and future directions for research.

Key Takeaways

  • Learn how ctDNA-based MRD testing can identify recurrence risk and guide treatment decisions in HNSCC.
  • Understand how MRD testing enables earlier detection of recurrence and may predict benefit from immunotherapy.
  • Gain practical insights from real-world case studies and explore future directions in MRD research

All Events

SignateraTM Ultrasensitive MRD Testing for Head and Neck Cancer Patient Care

Upcoming Events

December

15

2025

12:00 PM - 12:45 PM Eastern Time (ET)

Virtual

Acknowledgement

Sponsored By

Natera